UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes

Cell metabolism, 2013-09, Vol.18 (3), p.333-340

2013

Volltextzugriff (PDF)

Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia

Diabetes care, 2005-07, Vol.28 (7), p.1547-1554

2005

Volltextzugriff (PDF)

Ethanol Induces Fatty Acid Synthesis Pathways by Activation of Sterol Regulatory Element-binding Protein (SREBP)

The Journal of biological chemistry, 2002-08, Vol.277 (32), p.29342-29347

2002

Volltextzugriff (PDF)

Pioglitazone and Rosiglitazone Have Different Effects on Serum Lipoprotein Particle Concentrations and Sizes in Patients With Type 2 Diabetes and Dyslipidemia

Diabetes care, 2007-10, Vol.30 (10), p.2458-2464

2007

Volltextzugriff (PDF)

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

Diabetes care, 2016-07, Vol.39 (7), p.1241-1249

2016

Volltextzugriff (PDF)

Dual-Monoclonal, Sandwich Immunoassay Specific for Glucose-Dependent Insulinotropic Peptide1-42, the Active Form of the Incretin Hormone

Clinical chemistry (Baltimore, Md.), 2011-06, Vol.57 (6), p.849-855

2011

Volltextzugriff (PDF)

Systemic Levels of Lipid Peroxidation and Its Metabolic and Dietary Correlates in Patients with Nonalcoholic Steatohepatitis

The American journal of gastroenterology, 2004-08, Vol.99 (8), p.1497-1502

2004

Volltextzugriff (PDF)

Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies

PPAR Research, 2008-01, Vol.2008 (2008), p.1-6

2008

Volltextzugriff (PDF)

Glycosylphosphatidylinositol-Specific Phospholipase D in Nonalcoholic Fatty Liver Disease: A Preliminary Study

The journal of clinical endocrinology and metabolism, 2006-06, Vol.91 (6), p.2279-2285

2006

Volltextzugriff (PDF)

Factors associated with stroke, myocardial infarction, ischemic heart disease, unstable angina, or mortality in patients from real world clinical practice with newly-diagnosed type 2 diabetes and early glycemic control

Current medical research and opinion, 2018-02, Vol.34 (2), p.337-343

2018

Volltextzugriff (PDF)

Characterization of human brain nicotinamide 5'-mononucleotide adenylyltransferase-2 and expression in human pancreas

Biochemical journal, 2004-01, Vol.377 (Pt 2), p.317-326

2004

Volltextzugriff (PDF)

Prognostic and predictive biomarkers of abdominal aortic aneurysm growth rate

Current medical research and opinion, 2016-03, Vol.32 (3), p.509-517

2016

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects

British journal of clinical pharmacology, 2014-12, Vol.78 (6), p.1334-1342

2014

Volltextzugriff (PDF)

Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients

Journal of clinical lipidology, 2016-05, Vol.10 (3), p.519-527.e4

2016

Volltextzugriff (PDF)

Glycosylphosphatidylinositol-specific phospholipase D influences triglyceride-rich lipoprotein metabolism

American journal of physiology: endocrinology and metabolism, 2006-03, Vol.290 (3), p.E463-E470

2006

Volltextzugriff (PDF)

Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249

Diabetes care, 2017-06, Vol.40 (6), p.808-808

2017

Volltextzugriff (PDF)

Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249

Diabetes care, 2016-11, Vol.39 (11), p.e199-e200

2016

Volltextzugriff (PDF)

GPI-specific phospholipase D associates with an apoA-I- and apoA-IV-containing complex

Journal of lipid research, 2001-03, Vol.42 (3), p.442-451

2001

Volltextzugriff (PDF)

Mutating His29, His125, His133 or His158 abolishes glycosylphosphatidylinositol-specific phospholipase D catalytic activity

Biochemical journal, 2005-10, Vol.391 (Pt 2), p.285-289

2005

Volltextzugriff (PDF)

A novel high-sensitivity electrochemiluminescence (ECL) sandwich immunoassay for the specific quantitative measurement of plasma glucagon

Clinical biochemistry, 2012-12, Vol.45 (18), p.1640-1644

2012

Volltextzugriff (PDF)

Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2019-01, Vol.18 (1), p.39-53

2019

Volltextzugriff (PDF)

Evaluation of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy After Single and Multiple Dosings of LY3016859 in Healthy Subjects and Patients With Diabetic Nephropathy

Clinical pharmacology in drug development, 2018-09, Vol.7 (7), p.759-772

2018

Volltextzugriff (PDF)

Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis

The American journal of gastroenterology, 2003-08, Vol.98 (8), p.1849-1855

2003

Volltextzugriff (PDF)

Glycosylphosphatidylinositol-specific phospholipase D improves glucose tolerance

Metabolism, clinical and experimental, 2010-10, Vol.59 (10), p.1413-1420

2010

Volltextzugriff (PDF)

1 – 25 von 153

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(141)
Mit Volltextzugriff
(127)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(153)
Japanisch
(20)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(99)
Life Sciences & Biomedicine
(94)
Humans
(79)
Male
(62)
Female
(49)
Biological And Medical Sciences
(32)
Aged
(29)
Middle Aged
(29)
Medical Sciences
(25)
Adult
(23)
Aged, 80 And Over
(20)
Animals
(20)
Endocrinology & Metabolism
(20)
Risk Factors
(16)
Osteoarthritis
(15)
Arthritis
(13)
Diabetes
(13)
Medicin Och Hälsovetenskap
(13)
Biochemistry & Molecular Biology
(11)
Fundamental And Applied Biological Sciences. Psychology
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes

Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia

Ethanol Induces Fatty Acid Synthesis Pathways by Activation of Sterol Regulatory Element-binding Protein (SREBP)

Pioglitazone and Rosiglitazone Have Different Effects on Serum Lipoprotein Particle Concentrations and Sizes in Patients With Type 2 Diabetes and Dyslipidemia

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

Dual-Monoclonal, Sandwich Immunoassay Specific for Glucose-Dependent Insulinotropic Peptide1-42, the Active Form of the Incretin Hormone

Systemic Levels of Lipid Peroxidation and Its Metabolic and Dietary Correlates in Patients with Nonalcoholic Steatohepatitis

Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies

Glycosylphosphatidylinositol-Specific Phospholipase D in Nonalcoholic Fatty Liver Disease: A Preliminary Study

The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)

Factors associated with stroke, myocardial infarction, ischemic heart disease, unstable angina, or mortality in patients from real world clinical practice with newly-diagnosed type 2 diabetes and early glycemic control

Characterization of human brain nicotinamide 5'-mononucleotide adenylyltransferase-2 and expression in human pancreas

Prognostic and predictive biomarkers of abdominal aortic aneurysm growth rate

Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects

Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients

Glycosylphosphatidylinositol-specific phospholipase D influences triglyceride-rich lipoprotein metabolism

Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249

Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249

GPI-specific phospholipase D associates with an apoA-I- and apoA-IV-containing complex

Mutating His29, His125, His133 or His158 abolishes glycosylphosphatidylinositol-specific phospholipase D catalytic activity

A novel high-sensitivity electrochemiluminescence (ECL) sandwich immunoassay for the specific quantitative measurement of plasma glucagon

Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis

Evaluation of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy After Single and Multiple Dosings of LY3016859 in Healthy Subjects and Patients With Diabetic Nephropathy

Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis

Glycosylphosphatidylinositol-specific phospholipase D improves glucose tolerance

Suchergebnisse filtern